Alogliptin

drugbox
IUPAC_name = 2-({6- [(3"R")-3-aminopiperidin-1-yl] -3-methyl-2,4-dioxo-
3,4-dihydropyrimidin-1(2"H")-yl}methyl)benzonitrile

---

CAS_number = 850649-62-6
ATC_prefix =
ATC_suffix =
PubChem = 11450633
DrugBank =
C=18|H=21|N=5|O=2
molecular_weight = 339.39 g/mol
smiles = N#Cc3ccccc3CN1C(=O)N(C)C(=O)/C=C/1N2CCC [C@@H] (N)C2
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class,cite journal |author=Feng J, Zhang Z, Wallace MB, "et al" |title=Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV |journal=J. Med. Chem. |volume=50 |issue=10 |pages=2297–300 |year=2007 |pmid=17441705 |doi=10.1021/jm070104l] being developed by Takeda Pharmaceutical Company. Takeda has submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials.cite press release | url = http://www.takeda.com/press/article_28864.html | title = Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | date = January 4 2008 | accessdate = 2008-01-09 | publisher = Takeda Pharmaceutical Company]

References